香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 宜明昂科生物醫藥技術（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1541） 自願公告 執行董事、首席執行官兼董事會董事長增持股份 本公告由宜明昂科生物醫藥技術（上海）股份有限公司（「本公司」，連同其附屬 公司統稱「本集團」）自願作出，以告知本公司股東及潛在投資者有關本公司執 行董事、首席執行官兼董事會（「董事會」）董事長田文志博士（「田博士」）增持 本公司股份。 董事會獲田博士告知，其已於2025年11月7日於公開市場購買合共50,000股本公 司H股，每股股份平均價格為約7.9500港元，佔本公司已發行股份（「股份」）總 數的約0.01%。緊隨購買後，田博士於合共116,084,090股股份中擁有權益，佔於 本公告日期本公司已發行股本總額的26.90%。 宜明昂科生物醫藥技術（上 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 宜明昂科生物醫藥技術（上海）股份有限公司（於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01541 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 396,277,305 | RMB | | 1 | RMB | | 396,277,305 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 396,277,305 | RMB | | 1 | RM ...

Major Events - Minglue Technology (02718) plans to offer 7.219 million Class A shares globally from October 23 to October 28, with cornerstone subscriptions amounting to $59 million [1] - Wisco Properties (00230) received a privatization offer from Wisco Hong Kong at a premium of approximately 104.08%, with trading resuming on October 24 [1] - Junyu Foundation (01757) was acquired by China Venture Capital Holdings for 75% of its shares at a discount of about 79.06%, with trading resuming on October 24 [1] - Kangda Foods (00834) was acquired by Gaosi Shi for approximately 54.69% of the company’s shares at a premium of about 16.23%, with trading resuming on October 24 [1] - Hutchison China MediTech (00013) presented data on HMPL-A251 at the AACR-NCI-EORTC International Conference on Molecular Targeted and Cancer Therapeutics [1] - Giant Bio (02367) received a medical device registration certificate for its Type I α1 collagen lyophilized fiber product [1] - Yiming Anke-B (01541) completed the first patient dosing in the Phase IB/II clinical trial of IMM2510 combined with IMM01 [1] - Heng Rui Medicine (01276) received approval to conduct clinical trials for injection of Rikan Trastuzumab [1] - Hansoh Pharmaceutical (03692) had its application for HS-10365 capsule marketing approval accepted by the National Medical Products Administration [1] - Baixin An-B (02185) completed market access and the first commercial surgery for the IBERIS® RDN system in Switzerland [1] - Haotian International Construction Investment (01341) purchased a total of 646 units of Ethereum as of October 23 [1] Share Buybacks/Reductions - Cornerstone Pharmaceuticals-B (02616) saw CEO Yang Jianxin and senior management purchase an additional 1 million shares [2] - Midea Group (00300) repurchased 1.3434 million A shares for approximately 99.998 million yuan on October 23 [2] - China Communications Construction (01800) repurchased 119.45 million A shares for approximately 10.5994 million yuan on October 23 [2] - Mengniu Dairy (02319) repurchased 700,000 shares for approximately 10.0692 million HKD on October 23 [2] - Lianlian Digital (02598) spent about 7.5555 million HKD to repurchase 967,000 shares on October 23 [2] - Lianyi Rong Technology-W (09959) repurchased 2.47 million shares for approximately 7.4137 million HKD on October 23 [2] - Heng Rui Medicine (01276) repurchased 97,500 A shares for approximately 6.2808 million yuan on October 23 [2] - Gushengtang (02273) repurchased 19,860 shares for approximately 5.8634 million HKD on October 23 [2] Operating Performance - Ping An Good Doctor (01833) reported total revenue of approximately 3.725 billion yuan for the first three quarters, a year-on-year increase of 13.6%, and plans to continue expanding AI technology to enhance medical service efficiency and quality [2] - Sands China Ltd. (01928) reported a 7.5% year-on-year increase in net revenue to $1.9 billion for the third quarter [2] - Livzon Pharmaceutical (01513) announced a net profit attributable to shareholders of 1.754 billion yuan for the first three quarters, a year-on-year increase of 4.86% [2] - China Railway Construction (01186) signed new contracts totaling 1.518765 trillion yuan in the first three quarters, a year-on-year increase of 3.08% [2] - Prada (01913) reported net revenue of 4.07 billion euros for the first three quarters, a year-on-year increase of 9% [2] Additional Performance Metrics - Baio Family Interactive (02100) reported 10.2 million active accounts in the third quarter, a year-on-year increase of 37.8% [3] - Anton Oilfield Services (03337) secured new orders worth 1.273 billion yuan in the third quarter [3]

Group 1 - The company has successfully completed the first patient dosing in the IB/II clinical trial of IMM2510 in combination with IMM01 for the treatment of advanced solid tumors, marking a significant milestone in innovative cancer immunotherapy [1] - IMM2510, developed by the company, is a bispecific molecule targeting VEGF and PD-L1, designed to inhibit angiogenesis, reduce tumor size, and enhance immune response sensitivity [1] - The mechanism of IMM2510 includes blocking the PD-L1/PD-1 interaction and inducing antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), activating T cells, natural killer cells, and macrophages [1] Group 2 - The company has entered into a licensing and collaboration agreement with Axion Bio, Inc., granting the company commercialization rights for IMM2510 in Greater China while allowing Axion Bio, Inc. exclusive rights for research, development, and commercialization outside Greater China [2] - The company's core product, IMM01, is the first SIRPα-Fc fusion protein to enter clinical stages in China, designed to activate macrophages by blocking the "don't eat me" signal and delivering the "eat me" signal [3] - IMM01 has received orphan drug designation from the FDA for first-line treatment of CMML in combination with azacitidine, demonstrating its potential in the market [3] - The company holds global intellectual property and commercialization rights for IMM01, with a patent family that includes granted patents in China, the US, Japan, and the EU [3]

Group 1 - Company has successfully completed the first patient dosing in the Phase IB/II clinical trial of IMM2510 in combination with IMM01 for the treatment of advanced solid tumors, marking a significant milestone in the field of innovative cancer immunotherapy [1] - IMM2510 (Perivalephap α) is a proprietary dual-specific molecule targeting Vascular Endothelial Growth Factor (VEGF) and Programmed Cell Death Ligand 1 (PD-L1), designed to inhibit angiogenesis, reduce tumor size, and enhance tumor cell sensitivity to immune responses [1] - The mechanism of IMM2510 includes blocking the PD-L1/Programmed Cell Death Protein 1 (PD-1) interaction and inducing Fc-mediated Antibody-Dependent Cellular Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP) to activate T cells, natural killer cells, and macrophages [1] Group 2 - The company has entered into a licensing and collaboration agreement with Axion Bio, Inc., granting the company commercialization rights for IMM2510 in Greater China while allowing Axion Bio, Inc. exclusive rights for research, development, and commercialization outside Greater China [2] - The core product IMM01 (Tidapepac) is an innovative molecule targeting CD47, recognized as the first SIRPα-Fc fusion protein to enter clinical stages in China, demonstrating a dual mechanism to activate macrophages [3] - IMM01 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for first-line treatment of Chronic Myelomonocytic Leukemia (CMML) in combination with Azacitidine, showcasing its potential in the market [3] - The company holds global intellectual property and commercialization rights for IMM01, with a patent family that includes granted patents in China, the United States, Japan, and the European Union [3]

Group 1 - Company announced the successful completion of the first patient dosing in the Phase IB/II clinical trial of IMM2510 in combination with IMM01 for the treatment of advanced solid tumors, marking a milestone in innovative cancer immunotherapy [1] - IMM2510 (Pervirafusp alpha) is a dual-specific molecule targeting Vascular Endothelial Growth Factor (VEGF) and Programmed Cell Death Ligand 1 (PD-L1), designed to inhibit angiogenesis, reduce tumor size, and enhance immune response sensitivity [1] - The mechanism of IMM2510 includes blocking the PD-L1/Programmed Cell Death Protein 1 (PD-1) interaction and inducing antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP), activating T cells, natural killer cells, and macrophages [1] Group 2 - The company entered into a licensing and collaboration agreement with Axion Bio, Inc., granting the company commercialization rights for IMM2510 in the Greater China region while allowing Axion Bio, Inc. exclusive rights for research, development, and commercialization outside this region [2] - The core product IMM01 (Tideglusib) is an innovative molecule targeting CD47, being the first SIRPα-Fc fusion protein to enter clinical stages in China, designed to activate macrophages through dual mechanisms [3] - IMM01 has received orphan drug designation from the FDA for first-line treatment of Chronic Myelomonocytic Leukemia (CMML) in combination with Azacitidine, showcasing its potential in the market [3] - The company holds global intellectual property and commercialization rights for IMM01, with a patent family that includes granted patents in China, the United States, Japan, and the European Union [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 宜明昂科生物醫藥技術（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1541） 自願公告 IMM2510（珀維拉芙普α）由本集團自主研發，是一款靶向血管內皮生長因子 (VEGF)及程序性細胞死亡配體1 (PD-L1)的雙特異性分子，採用單克隆抗體 — 受體重組蛋白(mAb-Trap)結構。IMM2510能夠抑制血管生成，使腫瘤縮小，並 使腫瘤細胞對免疫反應更敏感，同時通過阻斷PD-L1 ╱程序性細胞死亡蛋白1 (PD-1)相互作用及誘導Fc介導的抗體依賴的細胞毒性作用(ADCC) ╱抗體依賴的 細胞吞噬作用(ADCP)活性激活T細胞、自然殺傷細胞及巨噬細胞。 本公司與Axion Bio, Inc.（前稱為SynBioTx Inc.，Instil Bio, Inc. (NASDAQ：TI ...

Core Viewpoint - The company Yiming Anke-B (01541.HK) announced the issuance of 24.2 million shares according to a placement agreement, scheduled for October 16, 2025 [1] Group 1 - The issuance of shares is part of a placement agreement [1] - The total number of shares to be issued is 24.2 million [1] - The scheduled date for the issuance is October 16, 2025 [1]

Core Viewpoint - 宜明昂科-B (01541) announced the issuance of 24.2 million new H-shares based on a general authorization and a placement agreement dated October 9, 2025 [1] Group 1 - The company will allocate and issue a total of 24.2 million new H-shares [1]

Group 1 - The company, Yiming Anke-B (01541), announced the issuance of 24.2 million new H-shares based on a general authorization and a placement agreement dated October 9, 2025 [1]